| GENMAB AS DK 1 | 364.70 / -0.33% |
News
- Genmab Announces that Janssen has Received Positive CHMP Opinion Recommending DARZALEX® (daratumumab) Subcutaneous (SC) Formulation for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
05/21/2021 / 15:08 - GlobeNewswire - Genmab Announces Financial Results for the First Quarter of 2021
05/05/2021 / 17:01 - GlobeNewswire - Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2021
04/20/2021 / 12:34 - GlobeNewswire - Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
04/09/2021 / 22:00 - GlobeNewswire - Genmab Announces European Marketing Authorization for Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
03/30/2021 / 07:21 - GlobeNewswire - Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
02/25/2021 / 20:53 - GlobeNewswire - Genmab announces initiation of share buy-back program
02/23/2021 / 17:05 - GlobeNewswire - Genmab Publishes 2020 Annual Report
02/23/2021 / 17:00 - GlobeNewswire - Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medicines
02/22/2021 / 14:00 - GlobeNewswire - Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
02/10/2021 / 22:05 - GlobeNewswire - CHMP Issues Positive Opinion Recommending Ofatumumab in Relapsing Multiple Sclerosis
01/29/2021 / 18:10 - GlobeNewswire - Genmab Announces 2020 Net Sales of DARZALEX® (daratumumab)
01/26/2021 / 12:45 - GlobeNewswire - Genmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
01/15/2021 / 20:17 - GlobeNewswire - Genmab Achieves USD 40 Million Milestone in Collaboration with AbbVie
01/13/2021 / 15:20 - GlobeNewswire - Genmab Announces Phase 3 Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
01/04/2021 / 20:00 - GlobeNewswire
Real-time